Clinical Trial Update: BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) [Phase 3]

View source ↗

Summary

Phase 3 extension study assessing BG00012 monotherapy safety and efficacy in relapsing-remitting multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-12-31